Open AccessPrognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review
Author(s) -
Gebra Cuyún Carter,
Maitreyee Mohanty,
Keri Stenger,
Claudia Morato Guimaraes,
S Singuru,
Pradeep Basa,
Surjit Singh,
Vanita Tongbram,
Sherko Küemmel,
Valentina Guarneri,
Sara M. Tolaney
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s300869
Subject(s) - medicine , oncology , breast cancer , metastatic breast cancer , cancer , population , hormone receptor , gynecology , environmental health
Advanced breast cancer is a heterogeneous disease with several well-defined subtypes, among which, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) is most prevalent. Determination of HR and HER2 status influences prognosis and, thus, disease management. Although literature on these prognostic factors exist, especially in the early breast cancer setting, it remains unclear to what extent these factors can guide clinical decision-making in the advanced disease setting. Therefore, we sought to identify the strength and consistency of evidence for prognostic factors in patients with HR+/HER2- advanced breast cancer.